{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:21Z","timestamp":1791357261065,"version":"4.3.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T00:00:00Z","timestamp":1586390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s40261-020-00913-7","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T11:02:36Z","timestamp":1586430156000},"page":"459-468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Long-Acting Injectable Antipsychotics: Analysis of Prescription Patterns and Patient Characteristics in Mental Health from a Spanish Real-World Study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3938-7698","authenticated-orcid":false,"given":"Juan Antonio","family":"Garc\u00eda-Carmona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Simal-Aguado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Pilar","family":"Campos-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Valdivia-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Galindo-Tovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,9]]},"reference":[{"issue":"1","key":"913_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1017\/S2045796014000614","volume":"25","author":"B Moreno-K\u00fcstner","year":"2016","unstructured":"Moreno-K\u00fcstner B, Mayoral F, Navas-Campa\u00f1a D, Garc\u00eda-Herrera JM, Angona P, Mart\u00edn C, Rivas F. Prevalence of schizophrenia and related disorders in Malaga (Spain): results using multiple clinical databases. Epidemiol Psychiatr Sci. 2016;25(1):38\u201348. https:\/\/doi.org\/10.1017\/S2045796014000614.","journal-title":"Epidemiol Psychiatr Sci"},{"issue":"1","key":"913_CR2","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.schres.2006.06.003","volume":"86","author":"JL Ayuso-Mateos","year":"2006","unstructured":"Ayuso-Mateos JL, Gutierrez-Recacha P, Haro JM, Chisholm D. Estimating the prevalence of schizophrenia in Spain using a disease model. Schizophr Res. 2006;86(1):194\u2013201. https:\/\/doi.org\/10.1016\/j.schres.2006.06.003.","journal-title":"Schizophr Res"},{"key":"913_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jad.2015.05.048","volume":"184","author":"L Calv\u00f3-Perxas","year":"2015","unstructured":"Calv\u00f3-Perxas L, Garre-Olmo J, Vilalta-Franch J. Prevalence and sociodemographic correlates of depressive and bipolar disorders in Catalonia (Spain) using DSM-5 criteria. J Affect Disord. 2015;184:97\u2013103. https:\/\/doi.org\/10.1016\/j.jad.2015.05.048.","journal-title":"J Affect Disord."},{"key":"913_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.rpsmen.2012.10.002","volume":"6","author":"J Bobes","year":"2013","unstructured":"Bobes J, Iglesias-Garc\u00eda C, Garc\u00eda-Portilla Gonz\u00e1lez MP, Bascar\u00e1n MT, Jim\u00e9nez-Trevi\u00f1o L, Pelayo-Ter\u00e1n JM, Rodr\u00edguez-Revuelta J, S\u00e1nchez-Lasheras F, S\u00e1iz-Mart\u00ednez P. Changes in administrative prevalence of mental disorders over a 13-year period in Asturias (northern Spain). Rev Psiquiatr Salud Ment. 2013;6:60\u20136. https:\/\/doi.org\/10.1016\/j.rpsmen.2012.10.002.","journal-title":"Rev Psiquiatr Salud Ment"},{"issue":"2","key":"913_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.gaceta.2011.12.006","volume":"27","author":"E Aragon\u00e9s","year":"2013","unstructured":"Aragon\u00e9s E, Salvador-Carulla L, L\u00f3pez-Muntaner J, Ferrer M, Pi\u00f1ol JL. Registered prevalence of borderline personality disorder in primary care databases. Gac Sanit. 2013;27(2):171\u20134. https:\/\/doi.org\/10.1016\/j.gaceta.2011.12.006.","journal-title":"Gac Sanit"},{"key":"913_CR6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.31887\/DCNS.2015.17.1\/wgaebel","volume":"17","author":"W Gaebel","year":"2015","unstructured":"Gaebel W, Zielasek J. Focus on psychosis. Dialogues Clin Neurosci. 2015;17:9\u201318.","journal-title":"Dialogues Clin Neurosci"},{"key":"913_CR7","doi-asserted-by":"publisher","unstructured":"Maayan N, Quraishi SN, David A, Jayaswal A, Eisenbruch M, Rathbone J, Asher R, Adams CE. Fluphenazine decanoate (depot) and enanthate for schizophrenia. Cochrane Database Syst Rev. 2015;2:CD000307. https:\/\/doi.org\/10.1002\/14651858.cd000307.pub2.","DOI":"10.1002\/14651858.cd000307.pub2"},{"key":"913_CR8","unstructured":"Coutinho E, Fenton M, Quraishi S. Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses. Cochrane Database Syst Rev. 2000;(2):CD001164."},{"issue":"6","key":"913_CR9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/YIC.0000000000000040","volume":"29","author":"S Heres","year":"2014","unstructured":"Heres S, Kraemer S, Bergstrom RF, Detke H. Pharmacokinetics of olanzapine long-acting injection: the clinical perspective. Int Clin Psychopharmacol. 2014;29(6):299\u2013312. https:\/\/doi.org\/10.1097\/YIC.0000000000000040.","journal-title":"Int Clin Psychopharmacol."},{"issue":"5","key":"913_CR10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2147\/NDT.S3311","volume":"4","author":"M Rainer","year":"2008","unstructured":"Rainer M. Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsychiatr Dis Treat. 2008;4(5):919\u201327.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"20","key":"913_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/ijnp\/pyw116","volume":"1","author":"A Raoufinia","year":"2017","unstructured":"Raoufinia A, Peters-Strickland T, Nylander AG, Baker R, Eramo A, Jin N, Bricmont P, Repella J, McQuade R, Hertel P, Larsen F. Aripiprazole once-monthly 400\u00a0mg: comparison of pharmacokinetics, tolerability, and safety of deltoid versus gluteal administration. Int J Neuropsychopharmacol. 2017;1(20):295\u2013304. https:\/\/doi.org\/10.1093\/ijnp\/pyw116.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"913_CR12","first-page":"42","volume":"47","author":"M Morris","year":"2017","unstructured":"Morris M, Tarpada S. Long-acting injectable paliperidone palmitate: a review of efficacy and safety. Psychopharmacol Bull. 2017;47(2):42\u201352.","journal-title":"Psychopharmacol Bull."},{"key":"913_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyw018","author":"A Savitz","year":"2016","unstructured":"Savitz A, Xu H, Gopal S, Nuamah I, Ravenstijn P, Janik A, Schotte A, Hough D, Fleischhacker W. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharmacol. 2016. https:\/\/doi.org\/10.1093\/ijnp\/pyw018.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"11","key":"913_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/2045125318782694","volume":"8","author":"E Stip","year":"2018","unstructured":"Stip E, Lachaine J. Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec. Ther Adv Psychopharmacol. 2018;8(11):287\u2013301. https:\/\/doi.org\/10.1177\/2045125318782694.","journal-title":"Ther Adv Psychopharmacol"},{"key":"913_CR15","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","volume":"74","author":"J Tiihonen","year":"2017","unstructured":"Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74:686\u201393.","journal-title":"JAMA Psychiatry"},{"key":"913_CR16","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","volume":"378","author":"A Cipriani","year":"2011","unstructured":"Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011;378:1306\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(11)60873-8.","journal-title":"Lancet"},{"key":"913_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/1471-244X-13-340","volume":"13","author":"P Llorca","year":"2013","unstructured":"Llorca P, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013;13:340\u201357.","journal-title":"BMC Psychiatry"},{"issue":"6","key":"913_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/YIC.0000000000000095","volume":"30","author":"N Palomares","year":"2015","unstructured":"Palomares N, Montes A, D\u00edaz-Mars\u00e1 M, Carrasco JL. Effectiveness of long-acting paliperidone palmitate in borderline personality disorder. Int Clin Psychopharmacol. 2015;30(6):338\u201341. https:\/\/doi.org\/10.1097\/YIC.0000000000000095.","journal-title":"Int Clin Psychopharmacol."},{"issue":"2","key":"913_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00213-012-2880-0","volume":"224","author":"JL Carrasco","year":"2012","unstructured":"Carrasco JL, Palomares N, Mars\u00e1 MD. Effectiveness and tolerability of long-acting intramuscular risperidone as adjuvant treatment in refractory borderline personality disorder. Psychopharmacology. 2012;224(2):347\u20138. https:\/\/doi.org\/10.1007\/s00213-012-2880-0.","journal-title":"Psychopharmacology"},{"key":"913_CR20","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4834135","author":"V Corigliano","year":"2018","unstructured":"Corigliano V, Comparelli A, Mancinelli I, Montalbani B, Lamis DA, Carolis A, Erbuto D, Girardi P, Pompili M. Long-acting injectable second-generation antipsychotics improve negative symptoms and suicidal ideation in recent diagnosed schizophrenia patients: a 1-year follow-up pilot study. Schizophr Res Treat. 2018. https:\/\/doi.org\/10.1155\/2018\/4834135.","journal-title":"Schizophr Res Treat"},{"issue":"5","key":"913_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.9740\/mhc.2016.09.248","volume":"6","author":"CN Carr","year":"2016","unstructured":"Carr CN, Hall CP, Roche-Desilets JE, Burant CJ, Fuller MA. Evaluation of adherence in patients prescribed long-acting injectable antipsychotics: a comparison of biweekly versus monthly administered neuroleptics. Ment Health Clin. 2016;6(5):248\u201353. https:\/\/doi.org\/10.9740\/mhc.2016.09.248.","journal-title":"Ment Health Clin"},{"issue":"9","key":"913_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.5414\/CP203427","volume":"57","author":"P Guillon","year":"2019","unstructured":"Guillon P, Harmand S, Ansolabehere X. Real-life persistence of long-acting injectable antipsychotics in schizophrenic patients: a retrospective observational study in France. Int J Clin Pharmacol Ther. 2019;57(9):437\u201344. https:\/\/doi.org\/10.5414\/CP203427.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"913_CR23","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008.","journal-title":"J Clin Epidemiol"},{"key":"913_CR24","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.schres.2019.08.001","volume":"212","author":"JA Mart\u00ednez-Andr\u00e9s","year":"2019","unstructured":"Mart\u00ednez-Andr\u00e9s JA, Garc\u00eda-Carmona JA. Clozapine, a controversial gold standard antipsychotic for the 21st century: switching to paliperidone palmitate 3-monthly improves the metabolic profile and lowers antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort. Schizophr Res. 2019;212:234\u20136.","journal-title":"Schizophr Res"},{"key":"913_CR25","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/schbul\/sbv037","volume":"41","author":"S Leucht","year":"2015","unstructured":"Leucht S, Samara M, Heres S, et al. Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull. 2015;41:1397\u2013402.","journal-title":"Schizophr Bull"},{"key":"913_CR26","unstructured":"Ashton CH. Benzodiazepines: how they work and how to withdrawn. Paperback, 2006."},{"key":"913_CR27","unstructured":"Villa LF. Medimecum gu\u00eda de terapia farmacol\u00f3gica. Ed Medilogic 2016."},{"issue":"7","key":"913_CR28","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s10597-015-9874-4","volume":"52","author":"J Saavedra","year":"2016","unstructured":"Saavedra J, L\u00f3pez M, Gonz\u00e1lez S, Arias S, Crawford P. Cognitive and social functioning correlates of employment among people with severe mental illness. Community Ment Health J. 2016;52(7):851\u20138. https:\/\/doi.org\/10.1007\/s10597-015-9874-4.","journal-title":"Community Ment Health J"},{"key":"913_CR29","unstructured":"Instituto Nacional Estad\u00edstica. Encuesta Nacional de Salud 2017. MSCBS-INE."},{"key":"913_CR30","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.pnpbp.2017.06.026","volume":"79","author":"J Mallet","year":"2017","unstructured":"Mallet J, Le Strat Y, Sch\u00fcrhoff F, Mazer N, Portalier C, Andrianarisoa M, Aouizerate B, Berna F, Brunel L, Capdevielle D, Chereau I, D\u2019Amato T, Denizot H, Dubreucq J, Faget C, Gabayet F, Lan\u00e7on C, Llorca PM, Misdrahi D, Rey R, Roux P, Schandrin A, Urbach M, Vidailhet P, Fond G, Dubertret C. Cigarette smoking and schizophrenia: a specific clinical and therapeutic profile? Results from the FACE-Schizophrenia cohort. Prog Neuropsychopharmacol Biol Psychiatry. 2017;79:332\u20139. https:\/\/doi.org\/10.1016\/j.pnpbp.2017.06.026.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"913_CR31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","volume":"191","author":"GE Hunt","year":"2018","unstructured":"Hunt GE, Large MM, Cleary M, Lai HMX, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990\u20132017: systematic review and meta-analysis. Drug Alcohol Depend. 2018;191:234\u201358.","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"913_CR32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1176\/appi.neuropsych.13110335","volume":"26","author":"J Victoroff","year":"2014","unstructured":"Victoroff J, Coburn K, Reeve A, Sampson S, Shillcutt S. Pharmacological management of persistent hostility and aggression in persons with schizophrenia spectrum disorders: a systematic review. J Neuropsychiatry Clin Neurosci. 2014;26(4):283\u2013312. https:\/\/doi.org\/10.1176\/appi.neuropsych.13110335.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"913_CR33","doi-asserted-by":"publisher","DOI":"10.3371\/csrp.buro.061518","author":"M Buoli","year":"2018","unstructured":"Buoli M, Rovera C, Esposito CM, Grassi S, Cahn W, Altamura AC. The use of long-acting antipsychotics for the management of aggressiveness in schizophrenia: a clinical overview. Clin Schizophr Relat Psychoses. 2018. https:\/\/doi.org\/10.3371\/csrp.buro.061518.","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"1","key":"913_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1517\/14740338.2015.974549","volume":"14","author":"R Musil","year":"2015","unstructured":"Musil R, Obermeier M, Russ P, Hamerle M. Weight gain and antipsychotics: a drug safety review. Expert Opin Drug Saf. 2015;14(1):73\u201396. https:\/\/doi.org\/10.1517\/14740338.2015.974549.","journal-title":"Expert Opin Drug Saf."},{"key":"913_CR35","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, B\u00e4ckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(19)31135-3.","journal-title":"Lancet"},{"issue":"10","key":"913_CR36","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00228-018-2498-1","volume":"74","author":"ELA Ribeiro","year":"2018","unstructured":"Ribeiro ELA, de Lima Mendon\u00e7a T, Vieira MEB, Storpirtis S, Aguiar PM. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. Eur J Clin Pharmacol. 2018;74(10):1215\u201333. https:\/\/doi.org\/10.1007\/s00228-018-2498-1.","journal-title":"Eur J Clin Pharmacol."},{"issue":"4","key":"913_CR37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/jamapsychiatry.2017.4711","volume":"75","author":"M L\u00e4hteenvuo","year":"2018","unstructured":"L\u00e4hteenvuo M, Tanskanen A, Taipale H, Hoti F, Vattulainen P, Vieta E, Tiihonen J. Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a finnish nationwide cohort of patients with bipolar disorder. JAMA Psychiatry. 2018;75(4):347\u201355. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.4711.","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"913_CR38","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1177\/2045125318795130","volume":"8","author":"JM Stone","year":"2018","unstructured":"Stone JM, Roux S, Taylor D, Morrison PD. First-generation versus second-generation long-acting injectable antipsychotic drugs and time to relapse. Ther Adv Psychopharmacol. 2018;8(12):333\u20136. https:\/\/doi.org\/10.1177\/2045125318795130.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"10","key":"913_CR39","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1017\/S0033291717003051","volume":"48","author":"R Patel","year":"2018","unstructured":"Patel R, Chesney E, Taylor M, Taylor D, McGuire P. Is paliperidone palmitate more effective than other long-acting injectable antipsychotics? Psychol Med. 2018;48(10):1616\u201323. https:\/\/doi.org\/10.1017\/S0033291717003051.","journal-title":"Psychol Med"},{"issue":"3","key":"913_CR40","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.4088\/JCP.13m08563","volume":"75","author":"WW Fleischhacker","year":"2014","unstructured":"Fleischhacker WW, Kane JM, Geier J, et al. Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial. J Clin Psychiatry. 2014;75(3):e184\u201390.","journal-title":"J Clin Psychiatry"},{"key":"913_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/bmb\/ldr042","volume":"100","author":"K Windfuhr","year":"2011","unstructured":"Windfuhr K, Kapur N. Suicide and mental illness: a clinical review of 15\u00a0years findings from the UK National Confidential Inquiry into Suicide. Br Med Bull. 2011;100:101\u201321. https:\/\/doi.org\/10.1093\/bmb\/ldr042.","journal-title":"Br Med Bull"},{"issue":"2","key":"913_CR42","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1034\/j.1600-0447.2000.102002118.x","volume":"102","author":"KH Suominen","year":"2000","unstructured":"Suominen KH, Isomets\u00e4 ET, Henriksson MM, Ostamo AI, L\u00f6nnqvist JK. Suicide attempts and personality disorder. Acta Psychiatr Scand. 2000;102(2):118\u201325.","journal-title":"Acta Psychiatr Scand"},{"key":"913_CR43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1192\/bjp.188.2.135","volume":"188","author":"I Hunt","year":"2006","unstructured":"Hunt I, Kapur N, Robinson J, et al. Suicide within 12\u00a0months of mental health service contact in different age and diagnostic groups. Br J Psychiatry. 2006;188:135\u201342.","journal-title":"Br J Psychiatry"},{"key":"913_CR44","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4834135","author":"V Corigliano","year":"2018","unstructured":"Corigliano V, Comparelli A, Mancinelli I, Montalbani B, Lamis DA, Carolis A, Erbuto D, Girardi P, Pompili M. Long-acting injectable second-generation antipsychotics improve negative symptoms and suicidal ideation in recent diagnosed schizophrenia patients: a 1-year follow-up pilot study. Schizophr Res Treat. 2018. https:\/\/doi.org\/10.1155\/2018\/4834135.","journal-title":"Schizophr Res Treat"},{"issue":"4","key":"913_CR45","doi-asserted-by":"publisher","first-page":"454","DOI":"10.2174\/1871527316666170223163629","volume":"16","author":"M Pompili","year":"2017","unstructured":"Pompili M, Orsolini L, Lamis DA, Goldsmith DR, Nardella A, Falcone G, Corigliano V, Luciano M, Fiorillo A. Suicide prevention in schizophrenia: do long-acting injectable antipsychotics (LAIs) have a role? CNS Neurol Disord Drug Targets. 2017;16(4):454\u201362.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"2","key":"913_CR46","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/0269881114541013","volume":"29","author":"F Sim","year":"2015","unstructured":"Sim F, Sweetman I, Kapur S, Patel MX. Re-examining the role of benzodiazepines in the treatment of schizophrenia: a systematic review. J Psychopharmacol. 2015;29(2):212\u201323. https:\/\/doi.org\/10.1177\/0269881114541013.","journal-title":"J Psychopharmacol"},{"key":"913_CR47","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1001\/archgenpsychiatry.2011.1532","volume":"69","author":"J Tiihonen","year":"2012","unstructured":"Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatr. 2012;69:476\u201383.","journal-title":"Arch Gen Psychiatr"},{"issue":"9896","key":"913_CR48","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, L\u00e4ssig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(13)60733-3.","journal-title":"Lancet"},{"key":"913_CR49","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2147\/NDT.S112063","volume":"13","author":"A Jariyavilas","year":"2017","unstructured":"Jariyavilas A, Thavichachart N, Kongsakon R, Chantakarn S, Arunpongpaisal S, Chantarasak V, Jaroensook P, Kittiwattanagul K, Nerapusee O. Effects of paliperidone extended release on hostility among Thai patients with schizophrenia. Neuropsychiatr Dis Treat. 2017;13:141\u20136. https:\/\/doi.org\/10.2147\/NDT.S112063.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"913_CR50","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2174\/1570159X13666150115220221","volume":"13","author":"JE Thomas","year":"2015","unstructured":"Thomas JE, Caballero J, Harrington CA. The incidence of akathisia in the treatment of schizophrenia with aripiprazole, asenapine and lurasidone: a meta-analysis. Curr Neuropharmacol. 2015;13(5):681\u201391.","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"913_CR51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2165\/00002018-200022010-00006","volume":"22","author":"CH Miller","year":"2000","unstructured":"Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf. 2000;22(1):73\u201381.","journal-title":"Drug Saf"},{"key":"913_CR52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/JCP.0000000000000755","volume":"37","author":"E Dimitropoulos","year":"2017","unstructured":"Dimitropoulos E, Drogemuller L, Wong K. Evaluation of concurrent oral and long-acting injectable antipsychotic prescribing at the Minneapolis veterans affairs health care system. J Clin Psychopharmacol. 2017;37:5. https:\/\/doi.org\/10.1097\/JCP.0000000000000755.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"913_CR53","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/JCP.0000000000000353","volume":"35","author":"JA Doshi","year":"2015","unstructured":"Doshi JA, Pettit AR, Stoddard JJ, Zummo J, Marcus SC. Concurrent oral antipsychotic drug use among schizophrenia patients initiated on long-acting injectable antipsychotics post-hospital discharge. J Clin Psychopharmacol. 2015;35(4):442\u20136. https:\/\/doi.org\/10.1097\/JCP.0000000000000353.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"913_CR54","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/JCP.0b013e31825244f6","volume":"32","author":"NK Aggarwal","year":"2012","unstructured":"Aggarwal NK, Sernyak MJ, Rosenheck RA. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications. J Clin Psychopharmacol. 2012;32(3):323\u20138. https:\/\/doi.org\/10.1097\/JCP.0b013e31825244f6.","journal-title":"J Clin Psychopharmacol"},{"key":"913_CR55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0920-9964(02)00156-1","volume":"59","author":"SA Chong","year":"2003","unstructured":"Chong SA, Mythily G, Remington G. Clinical characteristics and associated factors in antipsychotic-induced akathisia of Asian patients with schizophrenia. Schizophr Res. 2003;59:67\u201371.","journal-title":"Schizophr Res"},{"key":"913_CR56","doi-asserted-by":"publisher","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","volume":"71","author":"SW Woods","year":"2010","unstructured":"Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry. 2010;71:463\u201374.","journal-title":"J Clin Psychiatry"},{"key":"913_CR57","unstructured":"Young SL, Taylor M, Lawrie S. \u201cFirst do no harm\u201d. A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol. 2014;1\u201310."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00913-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-020-00913-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-020-00913-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T23:44:59Z","timestamp":1617925499000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-020-00913-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,9]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["913"],"URL":"https:\/\/doi.org\/10.1007\/s40261-020-00913-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,9]]},"assertion":[{"value":"9 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors neither received public or private funding nor grants to carry out this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"None of the authors have any conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics and methodology issues approval for the study were granted by both the Research Ethics Committee of the Murcia Health Service and by the Ethics Committee of the San Antonio Catholic University of Murcia (UCAM) (CE031914). No identifiable information was retained or is presented in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}